VNN1 and bacterial urinary tract infection: This limitation, together with the scarcity of information on pantothenamide activity against uropathogens in relevant growth environments, rationalizes further investigation of pantothenamides against UPEC under conditions relevant to UTI, including analogs designed to be pantetheinase-resistant.